UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.4)*
CYTORI THERAPEUTICS, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
23283K105
(CUSIP Number)
DECEMBER 31, 2007
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS
FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB
CONTROL NUMBER.
SEC 1745 (12-02)
- ---------------------------------------- -------------------------------------- --------------------------------------
CUSIP No. 23283K105 13G/A Page 2 of 6 Pages
- ---------------------------------------- -------------------------------------- --------------------------------------
- --------- ------------------------------------------------------------------------------------------------------------
1.
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
NEIL GAGNON
- --------- ------------------------------------------------------------------------------------------------------------
- --------- ------------------------------------------------------------------------------------------------------------
2.
CHECK THE APPROPRIATE BOX IF A GROUP* (a)
(b) |X|
- --------- ------------------------------------------------------------------------------------------------------------
- --------- ------------------------------------------------------------------------------------------------------------
3. SEC USE ONLY
- --------- ------------------------------------------------------------------------------------------------------------
- --------- ------------------------------------------------------------------------------------------------------------
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
UNITED STATES OF AMERICA
- --------- ------------------------------------------------------------------------------------------------------------
- ------------------- ----- --------------------------------------------- ----------------------------------------------
NUMBER OF 5.
SHARES SOLE VOTING POWER 1,365,628
- ------------------- ----- --------------------------------------------- ----------------------------------------------
- ------------------- ----- --------------------------------------------- ----------------------------------------------
BENEFICIALLY 6.
OWNED BY SHARED VOTING POWER 491,317
- ------------------- ----- --------------------------------------------- ----------------------------------------------
- ------------------- ----- --------------------------------------------- ----------------------------------------------
EACH 7.
REPORTING SOLE DISPOSITIVE POWER 1,296,415
- ------------------- ----- --------------------------------------------- ----------------------------------------------
- ------------------- ----- --------------------------------------------- ----------------------------------------------
PERSON WITH: 8.
SHARED DISPOSTIVE POWER 1,627,496
- ------------------- ----- --------------------------------------------- ----------------------------------------------
- --------- ---------------------------------------------------------------------------- -------------------------------
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,924,946
- --------- ---------------------------------------------------------------------------- -------------------------------
- --------- ------------------------------------------------------------------------------------------------------------
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
- --------- ------------------------------------------------------------------------------------------------------------
- --------- ---------------------------------------------------------------------------- -------------------------------
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 12.17%
- --------- ---------------------------------------------------------------------------- -------------------------------
- --------- ---------------------------------------------------------------------------- -------------------------------
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN
- --------- ---------------------------------------------------------------------------- -------------------------------
- ---------------------------------------- -------------------------------------- ----------------------------------------
CUSIP No. 23283K105 13G/A Page 3 of 6 Pages
- ---------------------------------------- -------------------------------------- ----------------------------------------
ITEM 1.
(a) Name of Issuer: CYTORI THERAPEUTICS, INC.
3020 CALLAN ROAD
(b) Address of Issuer's Principal Executive Offices: SAN DIEGO, CA 92121
ITEM 2.
(a) Name of Person Filing: NEIL GAGNON
(b) Address of Principal Business Office or, if none, Residence:
1370 AVE. OF THE AMERICAS, SUITE 2400 NEW YORK, NY 10019
(c) Citizenship: US
(d) Title of Class of Securities: COMMON STOCK, PAR VALUE $0.001 PER
SHARE
(e) CUSIP Number: 23283K105
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(B) OR
240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940
(15 U.S.C 80a-8).
(e) [ ] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with ss. 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance
Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the
Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
- ---------------------------------------- -------------------------------------- ----------------------------------------
CUSIP No. 23283K105 13G/A Page 4 of 6 Pages
- ---------------------------------------- -------------------------------------- ----------------------------------------
ITEM 4. OWNERSHIP.
Provide the following information regarding
the aggregate number and percentage of the
class of securities of the issuer identified
in Item 1. As of December 31, 2007, Neil
Gagnon beneficially owned 2,924,946 shares of
Common Stock of Cytori Therapeutics, Inc.,
which amount includes (i) 530,033 shares
beneficially owned by Mr. Gagnon over which
he has sole voting power and sole dispositive
power; (ii) 62,791 shares beneficially owned
by Mr. Gagnon over which he has sole voting
power and shared dispositive power; (iii)
286,561 shares beneficially owned by Lois
Gagnon, Mr. Gagnon's wife, over which he has
shared voting power and shared dispositive
power; (iv) 5,995 shares beneficially owed by
Mr. Gagnon and Mrs. Gagnon as Joint Tenants
with Rights of Survivorship, over which he
has shared voting power and shared
dispositive power; (v) 91,946 shares held by
the Lois E. and Neil E. Gagnon Foundation
(the "Foundation"), of which Mr. Gagnon is a
trustee and over which he has shared voting
power and shared dispositive power; (vi)
106,815 shares held by the Gagnon Family
Limited Partnership (the "Partnership") of
(a) Amount beneficially owned: which Mr. Gagnon is a partner and over which
he has shared voting power and shared
dispositive power; (vii) 96,701 shares held
by the Gagnon Grandchildren Trust (the
"Trust") over which Mr. Gagnon has shared
dispositive power but no voting power; (viii)
763,252 shares held by four hedge funds
(collectively, the "Funds"), of which Mr.
Gagnon is either the principal executive
officer of the manager or the managing member
of a member of the general partner or the
managing member and over which he has sole
dispositive power and sole voting power; (ix)
3,130 shares held by the Gagnon Securities
LLC Profit Sharing Plan and Trust (the
"Plan") of which Mr. Gagnon is a Trustee and
over which Mr. Gagnon has sole voting power
and sole dispositive power; (x) 7,457 shares
held by the Plan over which Mr. Gagnon has
sole voting power and shared dispositive
power; and (xi) 970,265 shares held for
certain customers of Gagnon Securities LLC,
of which Mr. Gagnon is the managing member
and the principal owner and over which he has
shared dispositive but no voting power.
12.17% beneficially owned by Mr. Gagnon.
Calculation of percentage of beneficial
ownership is based on 24,039,259 shares of
(b) Percent of class: Issuer's Common Stock outstanding as of
October 31, 2007, as reported by the Issuer
on its Form 10-Q for the period ended
September 30, 2007.
- ---------------------------------------- -------------------------------------- ----------------------------------------
CUSIP No. 23283K105 13G/A Page 5 of 6 Pages
- ---------------------------------------- -------------------------------------- ----------------------------------------
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
1,365,628
(ii) Shared power to vote or to direct the vote:
491,317
(iii) Sole power to dispose or to direct the disposition
of: 1,296,415
(iv) Shared power to dispose or to direct the disposition
of: 1,627,496
ITEM 5-9 Not Applicable
Filing of this statement by Mr. Gagnon shall not bee deemed an admission that he
beneficially owns the securities reported herein as held in customer accounts at
Gagnon Securities LLC or by the Foundation, the Partnership, the Trust, the
Funds or the Plan. Mr. Gagnon expressly disclaims beneficial ownership of all
securities held in such customer accounts or by the Foundation, the Partnership,
the Trust, the Funds or Plan. No single client's interest as reported in the
customer accounts at Gagnon Securities LLC exceeds 5% of the outstanding Common
Stock of the Issuer.
ITEM 10. CERTIFICATION
The following certification shall be included if the statement
is filed pursuant to ss.240.13d-1(b):
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above
were acquired and are held in the ordinary course of
business and were not acquired and are not held for the
(a) purpose of or with the effect of changing or
influencing the control of the issuer of the securities
and were not acquired and are not held in connection
with or as a participant in any transaction having that
purpose or effect. [X]
- ---------------------------------------- -------------------------------------- --------------------------------------
CUSIP No. 23283K105 13G/A Page 6 of 6 Pages
- ---------------------------------------- -------------------------------------- --------------------------------------
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 11, 2008
- -----------------
Date
/s/ Neil Gagnon
- ---------------
Signature
Neil Gagnon
Name/Title
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative other than an executive
officer or general partner of the filing person, evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. SEE ss.240.13d-7 for other
parties for whom copies are to be sent.
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)